Bristol-Myers Squibb Receives FDA Approval For New Formulation Of Antiretroviral Reyataz

Fri, 27 Oct 2006 04:00 AM EST

... Bristol-Myers Squibb on Friday announced that it has received FDA approval for a single 300 mg capsule formulation of its protease inhibitor Reyataz to be taken as part of combination therapy, Reuters reports. The new formulation is taken once daily and likely will be available within one week, according to BMS (Reuters, 10/20). [click link for full article] ...